Table 2.

PRR scores of PRR-based signals (the signals detected by the PRR method).

	All		Detected by EBGM		Not detected by EBGM		p
	N	PRR	N	PRR	N	PRR
Cisplatin	479	8.03 ± 11.29	175	12.90 ± 16.73	304	5.23 ± 4.36	< 0.001
Carboplatin	409	6.80 ± 8.32	144	10.57 ± 12.25	265	4.76 ± 3.69	< 0.001
Oxaliplatin	410	7.72 ± 11.47	150	11.69 ± 17.16	260	5.43 ± 4.90	< 0.001
Colistin	71	29.30 ± 83.82	23	77.31 ± 136.92	48	6.29 ± 4.66	< 0.001
5-Fluorouracil	461	7.52 ± 10.03	161	11.61 ± 14.90	300	5.33 ± 4.72	< 0.001
Capecitabine	411	8.09 ± 13.06	146	12.07 ± 20.26	265	5.90 ± 5.09	< 0.001
Pravastatin	218	4.70 ± 4.26	19	10.48 ± 8.61	199	4.15 ± 3.11	< 0.001
Simvastatin	192	4.50 ± 4.81	30	8.99 ± 10.33	162	3.66 ± 1.94	< 0.001
Atorvastatin	284	3.76 ± 1.93	55	4.41 ± 1.99	229	3.61 ± 1.89	< 0.001
Rosuvastatin	227	5.20 ± 5.77	63	8.50 ± 9.37	164	3.94 ± 2.65	< 0.001
Tigecycline	91	37.88 ± 114.30	44	72.09 ± 158.16	47	5.85 ± 3.57	< 0.001
Omeprazole	213	4.69 ± 5.05	14	12.29 ± 15.28	199	4.16 ± 2.77	0.003
Esomeprazole	194	4.65 ± 3.83	17	7.19 ± 9.50	177	4.41 ± 2.68	0.513
Warfarin	331	5.28 ± 4.95	110	7.46 ± 7.38	221	4.19 ± 2.47	< 0.001
Aspirin	348	5.56 ± 4.93	100	8.05 ± 7.39	248	4.56 ± 2.96	< 0.001
Clopidogrel	366	4.85 ± 3.79	104	6.77 ± 5.44	262	4.08 ± 2.52	< 0.001

PRR-based signals were divided into 2 groups based on whether adverse events were also detected by the EBGM method.